Skip to main content

Table 1 Stratification according to risk for recurrence prior to randomization according to predefined groups and distribution of BEXIDEM and BCG among the risk groups.

From: The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial

Group

TNM Classification

Number of Tumors

BEXIDEM®

BCG

A

Ta Grade 1

T1 Grade 1

Single or multiple

Single

26

29

B

Ta Grade 2

T1 Grade 1

T1 Grade 2

Single or multiple

Multiple

Single

26

26

C

Ta Grade 3

T1 Grade 2

Single or multiple

Multiple

23

23